WuXi Biologics makes Forbes China ESG 50 list for 2026

By Public Technologies
  • WuXi Biologics was named to the 2026 Forbes China ESG 50 list, cited for Green CRDMO execution and ESG digital innovation.
  • Forbes China highlighted an ESG data governance system spanning global operations, supporting quantified management and traceability.
  • Scope 1 and Scope 2 GHG emission intensity fell 30% versus 2020; water intensity dropped 32% versus 2019, beating a 30% target.
  • A Smart ESG platform was built to standardize ESG data collection, track indicators, support carbon inventory, resource use, waste management.
  • Green CRDMO tools cited include WuXiUI production technology, single-use manufacturing, digital dashboards for site-level performance monitoring.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wuxi Biologics (Cayman) Inc. published the original content used to generate this news brief on September 16, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.